Biological treatment for degenerative disc disease: implications for the field of physical medicine and rehabilitation

American Journal of Physical Medicine & Rehabilitation
Yejia ZhangD Greg Anderson

Abstract

Spine care is a fast-growing sector of the outpatient practice for physiatrists. Current nonsurgical treatment modalities and surgical options for severe symptomatic intervertebral disc degeneration have limited and inconsistent clinical results. Thus, the development of novel approaches, such as biological treatments that offer the potential to halt or even reverse disc degeneration and restore physiologic disc function, are very attractive. In this article, we first review the structural changes that occur during intervertebral disc degeneration and their relationship with discogenic back pain. Subsequently, we review the treatment approaches currently under clinical trial and laboratory investigation. Physiatrists specializing in spine care have the skill set required for administering intradiscal injections and supervising a comprehensive rehabilitation program after the procedures. Ultimately, the clinical use of any biological treatment discussed herein would require the collective efforts of physicians (such as physiatrists and surgeons) and researchers (such as chemical and biomedical engineers, biologists, and chemists).

References

Mar 1, 1991·Spine·J P ThompsonD S Bradford
Oct 1, 1989·Annals of Medicine·V Mooney
Jan 1, 1981·Connective Tissue Research·S HolmA Nachemson
Jan 1, 1995·Spine·A C SchwarzerN Bogduk
Oct 6, 1994·The New England Journal of Medicine·M BrittbergL Peterson
Mar 1, 1996·Archives of Physical Medicine and Rehabilitation·S J Dreyer, P H Dreyfuss
May 1, 1996·Clinical Orthopaedics and Related Research·M BrittbergL Peterson
Nov 1, 1996·The Journal of Bone and Joint Surgery. British Volume·M A AdamsP Dolan
Jan 12, 1999·Experimental Cell Research·D J AguiarT R Oegema
Apr 2, 1999·Science·M F PittengerD R Marshak
Sep 2, 1999·Lancet·G B Andersson
Jun 10, 2000·British Journal of Haematology·A EricesJ J Minguell
Sep 16, 2000·Experimental Hematology·R J Deans, A B Moseley
Oct 31, 2000·Current Opinion in Hematology·E Gluckman, F Locatelli
Feb 16, 2002·Science·Adam Bostanci
Mar 9, 2002·Journal of Gerontological Nursing·K C Buckwalter
Sep 25, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christiana DelloRussoJeffrey S Chamberlain
Oct 18, 2002·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Timothy M Ganey, Hans Joerg Meisel
Jun 24, 2004·American Journal of Physical Medicine & Rehabilitation·Yejia ZhangEugene J M A Thonar

❮ Previous
Next ❯

Citations

Feb 23, 2013·World Neurosurgery·Suk Hyung KangKwang Pil Ko
May 31, 2014·International Journal of Nanomedicine·Xinlin YangXudong Li
Jul 6, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Guo-Fu HuangBo-Yi Wang
May 18, 2012·Advances in Orthopedics·Doniel DrazinFrank Acosta
Apr 12, 2011·Apoptosis : an International Journal on Programmed Cell Death·Yue-Hui ZhangLi-Yang Dai
Dec 3, 2014·Advanced Drug Delivery Reviews·S B G BlanquerA A Poot
Dec 1, 2010·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Yun-Tao WangFeng Wang
Oct 28, 2010·Physical Medicine and Rehabilitation Clinics of North America·Ariana J VoraLee R Wolfer
Jul 29, 2015·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Tao GuRuan Dike
Mar 13, 2014·Journal of Tissue Engineering and Regenerative Medicine·Shahriar SharifiRoel Kuijer
Jul 25, 2009·Medicine, Health Care, and Philosophy·Leen TrommelmansKris Dierickx
Mar 25, 2011·Journal of Korean Neurosurgical Society·Suk-Hyung KangKwang Pil Ko
Sep 22, 2017·Tissue Engineering and Regenerative Medicine·S SchwanF Goehre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.